AbbVie

GlobalData’s patient-based forecast highlights that ADCs will see significant sales in the NSCLC space by 2032, led by…

The industry’s outlook remains uncertain as it navigates complex economic and political dynamics, reveals GlobalData

Approval marks Alembic’s 193rd final ANDA approval in the United States market

Tavapadon’s profile and efficacy could redefine its role in Parkinson’s treatment, but market positioning remains a challenge,…

Cobenfy is a twice-daily oral medication that combines xanomeline, a muscarinic receptor agonist, and trospium chloride, a…

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

Sionna Therapeutics secures exclusive global rights to develop and commercialise advanced CF compounds, strengthening its pipeline…

Strategic shift to Skyrizi and Rinvoq strengthens AbbVie's dominance in immunology despite Humira's biosimilar competition

Skyrizi (risankizumab) and Rinvoq (upadacitinib) are emerging as key replacements as sharp declines are expected for Humira

The campaign seeks to educate the public about risk factors associated with glaucoma, and promote regular eye check-ups,…